Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12213148 | 0.78 | — | — | |
| SCHEMBL1521714 | 0.76 | — | — | |
| SCHEMBL2307732 | 0.74 | — | — | |
| SCHEMBL2174113 | 0.74 | — | — | |
| SCHEMBL13763118 | 0.73 | TSHR (0.44) | L3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9030497 | 0.72 | TAAR1 (0.43) | ALDH1A1 | |
| SCHEMBL9243142 | 0.72 | TYR (0.38) | — | |
| SCHEMBL9663047 | 0.72 | CA2 (0.38) | — | |
| SCHEMBL957578 | 0.71 | MEN1 (0.40) | L3MBTL1ALDH1A1KEAP1 | |
| SCHEMBL9663893 | 0.71 | EDNRB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973051-B2 | Aminothiazoles as FBPase inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2227468-A1 | AMINOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | FBP1, SLC5A1, DPP4 | L3MBTL1 3174/4885ALDH1A1 525/4885ADRA1A 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.